HCW Biologics is trading at $2.30 (+8.49%) in pre-market, with no reliable company-specific announcement identified to explain the August 21, 2026 rebound.
- The latest official release, dated August 14, 2026, covered second-quarter results and clinical-development updates but did not explain the move.
- Lock-up expirations involving certain shares, options, and warrants were reported for August 20, 2026, but no source directly linked them to the gain.
- Broader futures were modestly higher, but the catalyst remains unclear.